Showing results (131-140 of 154) with videos related to

Sort By:
Pageof 16
Physics and Imaging in Radiation Oncology|December 1, 2025
A multi-institutional dummy run on segmentation variability and plan quality of stereotactic body radiotherapy for oligometastatic diseaseHideaki Hirashima, Yukinori Matsuo, Satoshi Ishikura, et al.
Breast Cancer (Tokyo, Japan)|February 18, 2021
Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort studyKiyo Tanaka, Norikazu Masuda, Naoki Hayashi, et al.
Annals of Surgical Oncology|February 18, 2026
Radiofrequency Ablation for Early Stage Breast Cancer as a Potential Alternative to Partial Mastectomy: 5-Year Results from the Multiple-Center, Single-Arm, Phase 3 RAFAELO Study (NCCH1409)Takayuki Kinoshita, Shin Takayama, Tomomi Fujisawa, et al.
Oncology Letters|January 25, 2019
Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancerYuichiro Miyoshi, Tadahiko Shien, Akiko Ogiya, et al.
Breast Cancer Research and Treatment|June 18, 2024
Baseline gut microbiota as a predictive marker for the efficacy of neoadjuvant chemotherapy in patients with early breast cancer: a multicenter prospective cohort study in the Setouchi Breast Project-14Shogo Nakamoto, Yukiko Kajiwara, Kohei Taniguchi, et al.
Biochemical and Biophysical Research Communications|August 2, 2020
Overcoming epithelial-mesenchymal transition-mediated drug resistance with monensin-based combined therapy in non-small cell lung cancerKosuke Ochi, Ken Suzawa, Shuta Tomida, et al.
Breast Cancer Research : BCR|July 3, 2016
Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrenceYuichiro Miyoshi, Tadahiko Shien, Akiko Ogiya, et al.
Acta Medica Okayama|June 28, 2021
Optimizing the timing of 3.6 mg Pegfilgrastim Administration for Dose-Dense Chemotherapy in Japanese Patients with Breast CancerDaisuke Takabatake, Yukiko Kajiwara, Shoichiro Ohtani, et al.
International Journal of Clinical Oncology|January 22, 2026
Clinical complete response and predictive factors in HER2-positive early breast cancer treated with neoadjuvant chemotherapy aimed at omission of surgery: an exploratory analysis of the JCOG1806 trialHideo Shigematsu, Tomomi Fujisawa, Fumikata Hara, et al.
The Oncologist|December 15, 2020
Current Status of Advance Care Planning and End-of-life Communication for Patients with Advanced and Metastatic Breast CancerYasuaki Sagara, Masanori Mori, Sena Yamamoto, et al.
Pageof 16